Well, if it is about discussions with the FDA, in my view that is likely positive.
But while I agree on some notions, I don’t agree that the many factors I pointed out all together are not incredibly unique. I’ve been in this space for years, so I am not just saying that... I think anyone living in this planet for 10 or mire years, well, make that 20, has to see that we’re in a hugely unique moment, not just because of the pandemic, but technologically also.
I think a lot more is going into this than just a label extension for a previously approved product, which should not even be in the list of comparables.
As for late filings, I don’t know if any count on this board is accurate or real on things like that, but I won’t dispute they have been late. Seeking extensions however, is not technically late in the same way as just being late. And I can’t comment on the S-3 allegation, again, many people say things on the board, those things turn into assumed “facts”, get repeated over and over again, but then can often turn out to not be accurate. Regardless, they have had some of the typical challenges of underfunded, distressed microcap bios. It’s why brokerages often block their retail investors from buying distressed penny stocks on the OTC.
However, it is not necessarily true that what is perceived as a delay, re TLD, is actually a “delay”, we simply do not have enough info to know what is going on. We surmise, because of company statements, that journal publication is a high priority. I think it is quite obvious why that would be the case. Moreover, I have seen articles with completed data, with incredibly good / excellent data, get delayed for long times. All for a variety of reasons. So I can’t say that anything is obvious at this stages
